Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors

Zihong Yan; Xiayun Huang; Hai-Qiu Wu; Wenxue Chen; Qiuqin He; Fen‐Er Chen; De Clercq Erik; Christophe Pannecouque

doi:10.1016/j.bmc.2014.02.030

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2014

Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors

Zihong Yan, Hai-Qiu Wu, Wenxue Chen, Yan Wu, Hu‐Ri Piao, Qiuqin He, Fen‐Er Chen, De Clercq Erik, Christophe Pannecouque

Article2020

Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs

Tingting Li, Christophe Pannecouque, De Clercq Erik, Chunlin Zhuang, Fen‐Er Chen

Article2005

Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase

Juliana Ruiz‐Caro, Aravind Basavapathruni, Joseph T. Kim, Christopher M. Bailey, Ligong Wang, Karen S. Anderson, Andrew D. Hamilton, William L. Jorgensen

Bioorganic & Medicinal Chemistry Letters

Article2006

Optimization of Diarylamines as Non‐Nucleoside Inhibitors of HIV‐1 Reverse Transcriptase.

Juliana Ruiz‐Caro, Aravind Basavapathruni, Joseph T. Kim, Christopher M. Bailey, Ligong Wang, Karen S. Anderson, Andrew D. Hamilton, William L. Jorgensen

ChemInform

Article2008

Non‐Nucleoside HIV‐1 Reverse‐Transcriptase Inhibitors. Part 10

Yueping Wang, Fen‐Er Chen, Jan Balzarini, De Clercq Erik, Christophe Pannecouque